Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study
Masaru Inatani, Akiyasu Kanamori, Maya Inai, Toshihiro Ikeda, Raymund Angeles · 2026
Read Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study by Masaru Inatani, Akiyasu Kanamori, Maya Inai, Toshihiro Ikeda, Raymund Angeles (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13452788.txt.
Description
Masaru Inatani and four co-authors report a phase 3 trial of sepetaprost, a new eye drop for glaucoma and high eye pressure. The drop works on two receptor types at once, unlike most older drops. Their 2026 trial, called ANGEL-J1, ran at 49 sites in Japan and randomly split 325 adults between sepetaprost and the standard drop latanoprost.
After four weeks, eye pressure fell by 5.77 points on the new drop against 6.10 points on the standard one, close enough to meet the trial's bar for matching it. Gains held across the full three months of daily use. Side effects hit 36.4 percent on sepetaprost against 20.2 percent on latanoprost, led by eye redness that was mostly mild. The team judges the drop a workable new choice with an acceptable safety record.
Catalog record
| CREATOR | Masaru Inatani, Akiyasu Kanamori, Maya Inai, Toshihiro Ikeda, Raymund Angeles |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34500 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |